Baker Bros. Advisors’s Syros Pharmaceuticals, Inc. Common Stock SYRS Stock Holding History

Baker Bros. Advisors’s Portfolio SYRS Stock Details SYRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-6,550	Closed	-$357K	–	129
2021 Q2	$357K	Sell	6,550 -62,467	-91%	-$3.7M	﹤0.01%	120
2021 Q1	$5.16M	Hold	69,017	–	–	0.02%	92
2020 Q4	$7.49M	Hold	69,017	–	–	0.03%	82
2020 Q3	$6.1M	Hold	69,017	–	–	0.02%	76
2020 Q2	$7.36M	Hold	69,017	–	–	0.03%	72
2020 Q1	$4.09M	Hold	69,017	–	–	0.03%	72
2019 Q4	$4.77M	Sell	69,017 -28,467	-29%	-$1.73M	0.03%	70
2019 Q3	$10.1M	Hold	97,484	–	–	0.07%	51
2019 Q2	$9.03M	Buy	97,484 +40,000	+70%	+$2.79M	0.06%	53
2019 Q1	$5.25M	Hold	57,484	–	–	0.03%	59
2018 Q4	$3.2M	Hold	57,484	–	–	0.03%	64
2018 Q3	$6.85M	Hold	57,484	–	–	0.05%	63
2018 Q2	$5.87M	Hold	57,484	–	–	0.04%	68
2018 Q1	$7.46M	Hold	57,484	–	–	0.06%	67
2017 Q4	$5.59M	Hold	57,484	–	–	0.05%	75
2017 Q3	$8.46M	Hold	57,484	–	–	0.07%	57
2017 Q2	$9.25M	Buy	57,484 +37,037	+181%	+$5.82M	0.08%	49
2017 Q1	$3.26M	Hold	20,447	–	–	0.03%	75
2016 Q4	$2.49M	Hold	20,447	–	–	0.02%	86
2016 Q3	$2.84M	Hold	20,447	–	–	0.03%	81
2016 Q2	$3.71M	Buy	+20,447	New	+$3.71M	0.04%	76

Other funds holding SYRS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ABG

Ally Bridge Group New York $124M AUM 249.88% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

OFM

Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Baker Bros. Advisors's SYRS Position: Q3 2021 in Review

Baker Bros. Advisors sold out of Syros Pharmaceuticals, Inc. Common Stock (SYRS) in Q3 2021, closing a stake of 6,550 shares — an estimated $357K sold.

Baker Bros. Advisors first reported a position in SYRS in Q2 2016 and held it in 21 quarters. The position peaked at $10.1M in Q3 2019. 100 funds tracked by Wall St. Rank hold SYRS as of Q3 2021.

Baker Bros. Advisors reported no remaining Syros Pharmaceuticals, Inc. Common Stock position as of Q3 2021 after selling out during the quarter.
Baker Bros. Advisors sold 6,550 Syros Pharmaceuticals, Inc. Common Stock shares in Q3 2021, an estimated $357K.
Baker Bros. Advisors first reported a position in Syros Pharmaceuticals, Inc. Common Stock in Q2 2016 and held it in 21 quarters.
Baker Bros. Advisors's Syros Pharmaceuticals, Inc. Common Stock position peaked at $10.1M in Q3 2019.
100 funds tracked by Wall St. Rank held Syros Pharmaceuticals, Inc. Common Stock as of Q3 2021.

Based on Baker Bros. Advisors's 13F filing for Q3 2021, filed 15 Nov 2021.